--- title: "Ligand Pharmaceuticals (LGND) news: offering" url: "https://aibio.space/companies/ligand-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "LGND offering, convertible notes, merger, lawsuit and buyback news: Ligand Pharmaceuticals completes $700.0 million 0.00% convertible senior notes offering." --- LGND Ligand Pharmaceuticals Incorporated NASDAQ · United States # Ligand Pharmaceuticals (LGND) news LGND offering, convertible notes, merger and lawsuit news Legal · 2026-10-29 ## [Viking and Ligand dispute VK2809 license termination in San Diego court](https://aibio.space/news/viking-ligand-dispute-vk2809-license-termination-san-diego-court/) Ligand sued Viking on May 19, 2026 after purporting to end the TR-Beta license. Viking cross-sued Ligand and Metabasis. A hearing on Ligand's demurrer is set for February 26, 2027. ## Latest Ligand Pharmaceuticals news 1. 2026-06-25 Debt Financing [Ligand Pharmaceuticals completes $700.0 million 0.00% convertible senior notes offering](https://aibio.space/news/ligand-pharmaceuticals-completes-700-0-million-0-00-percent/) Ligand closed $700.0 million of 0.00% convertible senior notes due 2031 after the initial purchasers exercised their option in full. Net proceeds were approximately $678.2 million, with about $72.9 million going to note hedges and approximately $60 million to a share repurchase. The initial conversion price is approximately $334.27 per share. 2. 2026-06-22 Debt Financing [Ligand plans $550 million of convertible notes due 2031](https://aibio.space/news/ligand-plans-550-million-convertible-notes-due-2031/) Ligand plans a private offering of $550.0 million of notes due 2031 to fund note hedges, a repurchase of up to $75 million of stock and general purposes, including a pending deal for Xoma Royalty Corporation. 3. 2026-04-27 Mergers [Ligand Pharmaceuticals signs merger agreement to acquire XOMA Royalty for $39.00 per share in cash](https://aibio.space/news/ligand-pharmaceuticals-signs-merger-agreement-acquire-xoma-royalty-39/) Ligand will pay about $739 million in equity value for XOMA Royalty, plus a contingent value right tied to litigation. The deal needs a XOMA Royalty stockholder vote and is expected to close in the third quarter of 2026. ## Ligand Pharmaceuticals at a glance - **Ticker**: LGND - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $1.36 billion ### Related companies - [HARD TO TREAT DISEASES INC](https://aibio.space/companies/hard-to-treat-diseases/) OTC: HTDS - [Ultragenyx Pharmaceutical](https://aibio.space/companies/ultragenyx-pharmaceutical/) NASDAQ: RARE - [Karyopharm Therapeutics](https://aibio.space/companies/karyopharm-therapeutics/) NASDAQ: KPTI - [Atossa Therapeutics](https://aibio.space/companies/atossa-therapeutics/) NASDAQ: ATOS - [Sunshine Biopharma](https://aibio.space/companies/sunshine-biopharma/) NASDAQ: SBFM - [Rhythm Pharmaceuticals](https://aibio.space/companies/rhythm-pharmaceuticals/) NASDAQ: RYTM - [NanoViricides](https://aibio.space/companies/nanoviricides/) AMEX: NNVC - [BeyondSpring](https://aibio.space/companies/beyondspring/) NASDAQ: BYSI ### Also on NASDAQ - [Jade Biosciences](https://aibio.space/companies/jade-biosciences/) JBIO - [Sight Sciences](https://aibio.space/companies/sight-sciences/) SGHT - [Vertex Pharmaceuticals](https://aibio.space/companies/vertex-pharmaceuticals/) VRTX - [Bioventus](https://aibio.space/companies/bioventus/) BVS - [DENTSPLY SIRONA](https://aibio.space/companies/dentsply-sirona/) XRAY - [Redhill Biopharma](https://aibio.space/companies/redhill-biopharma/) RDHL ## What Ligand Pharmaceuticals does Ligand Pharmaceuticals Incorporated is a biopharmaceutical royalty company that invests in and structures royalty interests in mid- to late-stage development and commercial biopharmaceutical products. Its revenue comes primarily from royalties on products its partners commercialize, supplemented by Captisol material sales and contract revenue from license fees and milestone payments. The company has 12 major commercial stage royalty assets and more than 90 additional commercial and development-stage programs. Its four strategies are royalty purchases, acquisitions of companies or assets with embedded royalty rights, project finance and other development-stage financing, and IP technology platform investments. Its platform technologies are Captisol and NITRICIL. Ligand describes past acquisitions that produced royalties, including Pharmacopeia, which yielded Travere's FILSPARI, Vernalis, which yielded Merck's Ohtuvayre, Pfenex, which yielded five of its major commercial royalty programs, and Novan, which yielded Zelsuvmi and the NITRICIL platform. Many of its investments take place under confidentiality agreements. | Product or program | What it is | Stage | |---|---|---| | Captisol | Royalty-generating platform technology with material sales | | | NITRICIL | Royalty-generating infrastructure-light platform technology | | | Commercial royalty portfolio | 12 major commercial stage royalty assets | commercial stage | Summarised from the company's [10-K filed Feb 27, 2026](https://www.sec.gov/Archives/edgar/data/886163/000088616326000006/lgnd-20251231.htm). ## Ligand Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$81.2 million](https://www.sec.gov/Archives/edgar/data/886163/000088616326000006/) | [$21.4 million](https://www.sec.gov/Archives/edgar/data/886163/000088616326000006/) | | Net income (loss) | [$124.5 million](https://www.sec.gov/Archives/edgar/data/886163/000088616326000006/) | [-$4.0 million](https://www.sec.gov/Archives/edgar/data/886163/000088616326000006/) | | Cash from operations | [$49.4 million](https://www.sec.gov/Archives/edgar/data/886163/000088616326000006/) | [$97.0 million](https://www.sec.gov/Archives/edgar/data/886163/000088616326000006/) | | Cash and equivalents | [$174.9 million](https://www.sec.gov/Archives/edgar/data/886163/000088616326000044/) | [$72.3 million](https://www.sec.gov/Archives/edgar/data/886163/000088616326000006/) | | Short-term investments | [$558.6 million](https://www.sec.gov/Archives/edgar/data/886163/000088616326000044/) | [$183.9 million](https://www.sec.gov/Archives/edgar/data/886163/000088616326000006/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $1.01 billion, plus short-term investments of $351.1 million, $1.36 billion in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Ligand Pharmaceuticals Has Ligand Pharmaceuticals raised money recently? Our latest story on this, dated Jun 25, 2026: "Ligand Pharmaceuticals completes $700.0 million 0.00% convertible senior notes offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ligand-pharmaceuticals-completes-700-0-million-0-00-percent/). Has Ligand Pharmaceuticals sold convertible notes? Our latest story on this, dated Jun 25, 2026: "Ligand Pharmaceuticals completes $700.0 million 0.00% convertible senior notes offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ligand-pharmaceuticals-completes-700-0-million-0-00-percent/). Is Ligand Pharmaceuticals involved in a merger or acquisition? Our latest story on this, dated Apr 27, 2026: "Ligand Pharmaceuticals signs merger agreement to acquire XOMA Royalty for $39.00 per share in cash". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ligand-pharmaceuticals-signs-merger-agreement-acquire-xoma-royalty-39/). Is Ligand Pharmaceuticals involved in a lawsuit? Our latest story on this, dated Oct 29, 2026: "Viking and Ligand dispute VK2809 license termination in San Diego court". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/viking-ligand-dispute-vk2809-license-termination-san-diego-court/). Does Ligand Pharmaceuticals have a share buyback? Our latest story on this, dated Jun 25, 2026: "Ligand Pharmaceuticals completes $700.0 million 0.00% convertible senior notes offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ligand-pharmaceuticals-completes-700-0-million-0-00-percent/). What is the ticker symbol of Ligand Pharmaceuticals? Ligand Pharmaceuticals Incorporated trades under the ticker LGND on NASDAQ. Where is Ligand Pharmaceuticals listed? Ligand Pharmaceuticals Incorporated is listed on NASDAQ. Our directory also records these other listings: GETTEX:LGDN; LS:A1C9RN; LSX:A1C9RN. What is the SEC CIK of Ligand Pharmaceuticals? The SEC Central Index Key (CIK) for Ligand Pharmaceuticals Incorporated is 886163. Its filings are on SEC EDGAR. How many shares does Ligand Pharmaceuticals have outstanding? 19,935,609 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-07. Which country or territory is Ligand Pharmaceuticals listed under? Our directory records Ligand Pharmaceuticals Incorporated under United States. What does Ligand Pharmaceuticals do? Our directory classifies Ligand Pharmaceuticals Incorporated as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Ligand Pharmaceuticals? The ISIN recorded for Ligand Pharmaceuticals Incorporated is US53220K5048. Does aibio.space cover Ligand Pharmaceuticals? aibio.space lists Ligand Pharmaceuticals Incorporated among 2,820 public biotech companies and publishes its news here as stories appear. Where is Ligand Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Ligand Pharmaceuticals develop? Ligand Pharmaceuticals Incorporated is a biopharmaceutical royalty company that invests in and structures royalty interests in mid- to late-stage development and commercial biopharmaceutical products. Its revenue comes primarily from royalties on products its partners commercialize, supplemented by Captisol material sales and contract revenue from license fees and milestone payments. ## Investor discussion: Ligand Pharmaceuticals Members talk about Ligand Pharmaceuticals (LGND). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Ligand Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-06-22 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/886163/000119312526276694/d41408dex991.htm) 2. 2026-04-30 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/886163/000088616326000027/lgnd-20260424.htm) 3. 2026-04-27 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,8.01). [Source](https://www.sec.gov/Archives/edgar/data/886163/000119312526179529/d143046dex991.htm) 4. 2026-02-27 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/886163/000119312526083241/d86418ds3asr.htm) 5. 2025-12-18 Financings Reported a financing. SEC Form 8-K (Items 7.01). [Source](https://www.sec.gov/Archives/edgar/data/886163/000119312525324830/d938301d8k.htm) 6. 2025-08-11 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/886163/000119312525177452/d434030dex991.htm) 7. 2025-04-17 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/886163/000088616325000020/lgnd-20250416.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:LGND on TradingView](https://www.tradingview.com/symbols/NASDAQ-LGND/). ## SEC filings and registration - **SEC name**: Ligand Pharmaceuticals Inc - **CIK**: 886163 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: LGND (Nasdaq), LGNDZ (OTC), LGNXZ (OTC), LGNYZ (OTC), LGNZZ (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA, 92121 - **Phone**: 858-550-7500 - **Shares outstanding**: 19,935,609 as of 2026-08-04 (10-Q filed 2026-08-07) - **Former names**: LIGAND PHARMACEUTICALS ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/886163/000088616326000054/lgnd-20260924.htm) filed 2026-09-24 - [8-K](https://www.sec.gov/Archives/edgar/data/886163/000088616326000050/lgnd-20260922.htm) filed 2026-09-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/886163/000088616326000044/lgnd-20260630.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/886163/000088616326000041/lgnd-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/886163/000119312526302660/d108457d8k.htm) filed 2026-07-14 - [8-K](https://www.sec.gov/Archives/edgar/data/886163/000119312526282990/d167360d8k.htm) filed 2026-06-25 - [8-K](https://www.sec.gov/Archives/edgar/data/886163/000119312526276694/d41408d8k.htm) filed 2026-06-22 - [8-K](https://www.sec.gov/Archives/edgar/data/886163/000088616326000038/lgnd-20260605.htm) filed 2026-06-09 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000886163), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Ligand Pharmaceuticals Incorporated is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LGND, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Ligand Pharmaceuticals Incorporated - **Ticker**: LGND - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US53220K5048 - **Other listed symbols**: GETTEX:LGDN; LS:A1C9RN; LSX:A1C9RN - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-LGND/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/ligand-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Ligand Pharmaceuticals (LGND) news: offering", 2026-10-31, https://aibio.space/companies/ligand-pharmaceuticals/